Show simple item record

dc.contributor.authorBruni, Cen_US
dc.contributor.authorFrech, Ten_US
dc.contributor.authorManetti, Men_US
dc.contributor.authorRossi, FWen_US
dc.contributor.authorFurst, DEen_US
dc.contributor.authorDe Paulis, Aen_US
dc.contributor.authorRivellese, Fen_US
dc.contributor.authorGuiducci, Sen_US
dc.contributor.authorMatucci-Cerinic, Men_US
dc.contributor.authorBellando-Randone, Sen_US
dc.date.accessioned2020-01-22T13:27:32Z
dc.date.available2018-08-20en_US
dc.date.issued2018en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/62486
dc.description.abstractThe early phase of systemic sclerosis (SSc) presents edema as one of the main features: this is clinically evident in the digital swelling (puffy fingers) as well as in the edematous skin infiltration of the early active diffuse subset. Other organs could be affected by this same disease process, such as the lung (with the appearance of ground glass opacities) and the heart (with edematous changes on cardiac magnetic resonance imaging). The genesis of tissue edema is tightly linked to pathological changes in the endothelium: various reports demonstrated the effect of transforming growth factor β, vascular endothelial growth factor and hypoxia-reperfusion damage with reactive oxygen species generation in altering vascular permeability and extravasation, in particular in SSc. This condition has an alteration in the glycocalyx thickness, reducing the protection of the vessel wall and causing non-fibrotic interstitial edema, a marker of vascular leak. Moreover, changes in the junctional adhesion molecule family and other adhesion molecules, such as ICAM and VCAM, are associated with an increased myeloid cells' extravasation in the skin and increased myofibroblasts transformation with further vascular leak and cellular migration. This mini-review examines current knowledge on determinants of vascular leak in SSc, shedding light on the role of vascular protection. This could enhance further studies in the light of drug development for early treatment, suggesting that the control of vascular leakage should be considered in the same way that vasodilation and inflammation reduction, as potential therapeutic targets.en_US
dc.format.extent2045 - ?en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofFront Immunolen_US
dc.rightsCreative Commons Attribution License
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectcapillary leaken_US
dc.subjectedemaen_US
dc.subjectendothelial dysfunctionen_US
dc.subjectextravasationen_US
dc.subjectpermeabilityen_US
dc.subjectsystemic sclerosisen_US
dc.subjectvasculopathyen_US
dc.subjectAnimalsen_US
dc.subjectBiomarkersen_US
dc.subjectCapillariesen_US
dc.subjectCapillary Permeabilityen_US
dc.subjectDisease Susceptibilityen_US
dc.subjectEndothelium, Vascularen_US
dc.subjectHumansen_US
dc.subjectImmune Systemen_US
dc.subjectLymphatic Diseasesen_US
dc.subjectScleroderma, Systemicen_US
dc.titleVascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?en_US
dc.typeArticle
dc.rights.holderBruni, Frech, Manetti, Rossi, Furst, De Paulis, Rivellese, Guiducci, Matucci-Cerinic and Bellando-Randone.
dc.identifier.doi10.3389/fimmu.2018.02045en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/30245695en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume9en_US
dcterms.dateAccepted2018-08-20en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution License
Except where otherwise noted, this item's license is described as Creative Commons Attribution License